PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Clinical Therapeutics, National and Kapodistrian University of Athens Medical School, Athens, Greece.\', \'Joint Rheumatology Program, First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens Medical School, 17 Agiou Thoma Street, 11527, Athens, Greece.\', \'Department of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK.\', \'Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, UK.\', \'Joint Rheumatology Program, First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens Medical School, 17 Agiou Thoma Street, 11527, Athens, Greece. psfikakis@med.uoa.gr.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1007/s00296-020-04629-x
?:doi
?:hasPublicationType
?:journal
  • Rheumatology international
is ?:pmid of
?:pmid
?:pmid
  • 32654078
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.906
?:rankingScore_hIndex
  • 62
is ?:relation_isRelatedTo_publication of
?:title
  • Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all